The estimated Net Worth of Capital, Llcstafford John S... is at least $108 Milion dollars as of 19 March 2020. Capital S owns over 77,570 units of Xencor Inc stock worth over $105,912,646 and over the last 13 years Capital sold XNCR stock worth over $2,274,352.
Capital has made over 32 trades of the Xencor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Capital sold 77,570 units of XNCR stock worth $2,274,352 on 19 March 2020.
The largest trade Capital's ever made was buying 1,238,052 units of Xencor Inc stock on 9 August 2019 worth over $3,602,731. On average, Capital trades about 78,395 units every 87 days since 2012. As of 19 March 2020 Capital still owns at least 5,012,430 units of Xencor Inc stock.
You can see the complete history of Capital S stock trades at the bottom of the page.
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford a John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Xencor Inc executives and other stock owners filed with the SEC include: